The Motley Fool··Eric VolkmanEli Lilly's Weight-Loss Drug Stumbles Out of Gate, Stock Drops Nearly 4%
Eli Lilly's new weight-loss drug Foundayo recorded just 3,707 prescriptions in week two, trailing Novo Nordisk's Wegovy by over 400%, triggering a 4% stock decline.
LLYNVOIQVstock declineFDA approval